European Infrastructure for Translational Medicine
General Info


Amsterdam, The Netherlands

legal status



physical, remote

EATRIS is the infrastructure for translational research, focusing on developing scientific discoveries into healthcare interventions. Translational research is highly inter-disciplinary, utilising advanced analytical technologies, clinical insights and regulatory compliant research execution to support robust validation of disease pathology and the development of new ways to diagnose and treat disease. A key feature of the EATRIS approach is ensuring patient co-creation at all steps of the development process, to ensure that clinical application is the goal at all times. Through its distributed infrastructure, which comprises over 150 leading research institutions in fourteen European countries (Bulgaria, Croatia, Czech Republic, Finland, France, Italy, Latvia, Netherlands, Norway, Portugal, Slovenia, Spain and Sweden) EATRIS supports both public and private research entities. The EATRIS Scientific Platforms (Biomarkers, Small Molecules, Imaging and Tracing, Advanced Therapy Medicinal Products (ATMPs), and Vaccines, Inflammation and Immune Monitoring) represent and structure the scientific and technology offering of the RI. The EATRIS scientific platforms are composed of academic and non-profit research institutions in biomedical translational research. All members possess well-established track records in entering clinical development, hosting unique infrastructures, licenses (such as Good Manufacturing Practice (GMP) laboratories), and clinical expertise with access to a broad array of patient cohorts. Each platform offers a specific set of infrastructure services targeted to the needs of its users (industry, academia, charity funders and governments). Biologists and clinical researchers work together using cutting-edge analytical platforms and innovative clinical models to gain a deep understanding of the biological process underlying a disease, and the mechanism by which a therapeutic may have an effect. EATRIS facilitates the interdisciplinary team science approach essential to successful translation, by bringing together laboratory, clinical, industrial, legal and regulatory expertise. Additionally, EATRIS institutes collaborate to overcome bottlenecks in translational research, for instance by undertaking standardisation and best practice exchange. EATRIS contributes to the development of biomedical sciences in the European Research Area providing Europe with a comprehensive Research Infrastructure helping to respond to challenges in science, industry and society and enable researchers to address societal challenges with a global dimension. EATRIS leading efforts can be illustrated with few examples of projects and initiatives such as Translation Together, a unique collaboration of leading translational research organisations from around the world with EATRIS being one of the original founders; EATRIS participation in IMI projects EU-PEARL and TRUSTroke or UMBRELLA as key partner leading the sustainability strategy; Glaxosmithkline (GSK) Imaging hub, developed and managed by EATRIS for GSK (large pharma) to deliver a clinical and scientific network for the development and application of innovative imaging methods for inflammatory diseases. Additionally, EATRIS coordinates REMEDi4ALL, an ambitious EU-funded research initiative focusing on repurposing medicines across Europe.
Total Investment 500 M€ Design Preparation 5 M€ Implementation 4,5 M€ Operation 2,5 M€/year Project Landmark 2006 2008 2010 2012 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2034 2036 2038 RM06 RM08 RM10 RM16 RM18 RM21 LA24
Roadmap Entry
as project: 2006
as landmark: 2016
Total investment
500 M€
Design Phase
Preparation Phase
5 M€
Implementation Phase
4,5 M€
Operation start
2,5 M€/year
At EATRIS we strive for a healthier future by transforming scientific breakthroughs into medical advancements for patients and society. We do this through impacting research, economy, innovation, and policy. Human capital impacts: EATRIS supports early career researchers with the knowledge and mindset needed to change the fundamentals of responsible research practices. EATRIS also supports capacity-building of its national nodes through training, staff exchanges and mobility programmes, which helps structuring and expanding research communities. Economic impacts: EATRIS enables new public private collaborations to be formed by matching industrial needs with academic expertise. Economic impacts are realised though the provision of research services and support to SME’s and large pharmaceutical companies in developing new medical/pharmaceutical solutions and products. Societal impacts: Improving patients' lives is central to EATRIS’ mission. By supporting all key stakeholders in research and development, EATRIS ultimately supports the transition of healthcare solutions and innovative products from the laboratory to the patient, from research to innovation. EATRIS also built-in its strategic development patient engagement activities with leading European patient organisations, such as the European Patients Forum and the European Patients’ Academy on Therapeutic Innovation (EUPATI). Policy impacts: EATRIS acts as a forum for open debate between the three sectors – academia, industry and funding organisation in order to improve communication, legal and regulatory alignment for the translational scientists; bringing patient’s voices at the center. EATRIS is also a strong advocate for Responsible Research and Innovation and has taken a leading role in policy debates on Reproducibility of Biomedical research and utilisation of European Research Infrastructures through ERIC Forum and the European Alliance of Medical Research Infrastructures (EU-AMRI).
User services and scientific and technological developments happen through EATRIS’ scientific platforms. The ATMPs platform for Gene Therapy Medicinal Products (GTMP), Cell Therapy Medicinal Products (CTMP), and Tissue Engineered Products (TEP); the Biomarkers platform facilitates the validation and development of biomarkers for the prevention, diagnosis and prognostic assessment of disease as well as for the prediction of therapy response while the Imaging and Tracing platform covers the entire scope of tracer development and molecular imaging. The EATRIS Small Molecules platform includes specialised academic expertise around novel targets and molecular scaffolds supporting drug development programmes and the EATRIS Vaccines, Inflammation and Immune Monitoring platform includes specialised GMP provision with accompanying formulation and adjuvant approaches; immune-monitoring, and access to clinical facilities. Innovation Management and exploitation, regulatory and health technology expertise belongs to EATRIS Expert Centres. Seven institutions in Spain, Italy and Portugal work under the EATRIS umbrella through an EATRIS Decentralised Expert Services Agreement. In addition, EATRIS offers a set of centralised digital tools and education and training portfolio such as the EATRIS Multi-omics Toolbox (MOTBX; an open access web resource related to multi-omics analysis), the Patient Engagement Resource Centre (PERC; dedicated to patient engagement materials) and the EATRIS Regulatory Information System (an overview of the regulatory requirements, guidelines and legislations from 27 EU countries). TransMed Academy is EATRIS’ online learning environment for translational scientists with a range of self-paced online courses, live courses, recorded webinars, and more.
EATRIS is working closely with Life Science RIs through EU-funded projects, such as ISIDORe and CanSERV, as well as through the LS RI Strategy Board. Through targeted bilateral collaborations EATRIS addresses complex challenges in focus areas such as with EUOPENSCREEN for the development of a workshop on drug discovery assay guidance or with CERN on the topics of artificial intelligence and medical imaging. Furthermore, EATRIS has signed a partnership agreement with BBMRI-ERIC and ECRIN creating EU-AMRI, the European Alliance for Medical Research Infrastructures. The three research infrastructures provide complementary services to researchers in the field of biomedical sciences and support the development of personalised medicine. Through EU-AMRI the infrastructures support the biomedical community through joint education and advocacy. EATRIS participates in the ERIC Forum second implementation project where it leads the Gender Equality and Gender Mainstreaming task working closely with ERICs from other disciplines beyond Life Sciences domain. EATRIS is also actively contributing to the Life Sciences Research Infrastructures Strategy Board which EATRIS chaired in 2019-2020.